GCM
TEVA icon

Glenview Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Glenview Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172M Sell
5,081,091
-1,579,129
-24% -$52.6M 3.13% 12
2026
Q1 		$201M Sell
6,660,220
-10,059,989
-60% -$324M 5.04% 5
2025
Q4 		$522M Buy
16,720,209
+27,529
+0.2% +$678K 10.62% 2
2025
Q3 		$337M Buy
16,692,680
+868,457
+5% +$15.3M 7.51% 5
2025
Q2 		$265M Buy
15,824,223
+1,045,582
+7% +$16.9M 7.43% 4
2025
Q1 		$227M Buy
14,778,641
+6,322,317
+75% +$113M 5.58% 4
2024
Q4 		$186M Hold
8,456,324
– – 4.71% 5
2024
Q3 		$152M Sell
8,456,324
-701,317
-8% -$12.3M 2.95% 11
2024
Q2 		$149M Buy
9,157,641
+1,656,357
+22% +$25.5M 2.93% 12
2024
Q1 		$106M Buy
7,501,284
+5,896,651
+367% +$74.3M 1.85% 16
2023
Q4 		$16.8M Buy
+1,604,633
New +$15M 0.36% 34
2016
Q4 		– Sell
-2,176,144
Closed -$100M – 52
2016
Q3 		$100M Sell
2,176,144
-906,703
-29% -$47.3M 0.72% 32
2016
Q2 		$155M Sell
3,082,847
-2,496,465
-45% -$133M 1.09% 25
2016
Q1 		$299M Sell
5,579,312
-376,484
-6% -$22.1M 2.18% 16
2015
Q4 		$391M Buy
5,955,796
+1,767,017
+42% +$109M 2.2% 17
2015
Q3 		$236M Buy
4,188,779
+1,344,379
+47% +$87.2M 1.17% 31
2015
Q2 		$168M Buy
+2,844,400
New +$175M 0.67% 48

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Glenview Capital Management's TEVA Position: Q2 2026 in Review

Glenview Capital Management reduced its Teva Pharmaceuticals (TEVA) stake by 24% in Q2 2026, selling an estimated $52.6M and leaving 5,081,091 shares worth $172M. The position accounts for 3.13% of the portfolio, ranked #12.

Glenview Capital Management first reported a position in TEVA in Q2 2015 and has held it in 17 quarters since. The position peaked at $522M in Q4 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Glenview Capital Management held 5,081,091 shares of Teva Pharmaceuticals worth $172M as of Q2 2026.
  • Glenview Capital Management sold 1,579,129 Teva Pharmaceuticals shares in Q2 2026, an estimated $52.6M.
  • Teva Pharmaceuticals made up 3.13% of Glenview Capital Management's portfolio in Q2 2026, its #12 holding.
  • Glenview Capital Management first reported a position in Teva Pharmaceuticals in Q2 2015 and has held it in 17 quarters since.
  • Glenview Capital Management's Teva Pharmaceuticals position peaked at $522M in Q4 2025.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Glenview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.